To target the high-intent search traffic for Tirzepatide (TRZ) while maintaining an authoritative, research-focused tone, the content must center on its classification as a dual-incretin agonist. In 2026, writing about TRZ means highlighting the synergistic relationship between the GIP and GLP-1 pathways, which sets it apart from older, single-targ